Somatostatin analogues incorporating nucleo amino acids have been chemically synthesised by both solution phase coupling of protected fragments and solid phase methods. Methodology is presented enabling the preparation of these previously unknown reduced size somatostatin analogues. The observation of high biological activity with modified receptor binding affinities and levels of inhibition of growth hormone release from cultured pituitary cells is discussed.